CytoKi Pharma is a pre-clinical biotechnology company with focus on serious diseases caused by epithelial injury having an unmet medical need.

Biotechnology

CytoKi Pharma

Karsten has extensive experience in non-clinical development and strategy. He has a background as CVP and area head with responsibility for all non-clinical development at Novo Nordisk and later a corresponding VP position at Ferring.

Karsten Skydsgaard

Anuj brings over 20 years’ experience working in senior leadership roles across the pharma/biotech sector, spanning across developments stages and functions and within numerous therapeutic areas and modalities.

Anuj most recently has been CEO at Zarodex Therapeutics, CBO at Topivert Pharma and VP Business Development at Jazz Pharmaceuticals. He is passionate about creating meaningful products for patients and has a strong track record of value creation for shareholders (>$2bn). Prior to his career in strategy & business development, he held positions in healthcare investment banking (HSBC, JP Morgan) and equity research (Bear Stearns).

Anuj Madhok

Professor Silvio Danese is Director of Gastroenterology at San Raffaele Hospital and Professor of Gastroenterology at Vita-Salute San Raffaele University, Milan.

Dr. Danese is a Member of many International Organizations, including UEG (Research Chair) and ECCO (Past President). He has published more than 750 articles and abstracts in International Congresses.

Silvio Danese

David T. Rubin is the Joseph B. Kirsner Professor of Medicine, Chief of the Section of Gastroenterology, Hepatology & Nutrition at the University of Chicago Medicine.

Dr. Rubin earned a medical degree with honors at The University of Chicago Pritzker School of Medicine where he also completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics. He is associate faculty member at the MacLean Center for Clinical Medical Ethics, associate investigator at the University of Chicago Comprehensive Cancer Center and a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation. Dr. Rubin twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), and in 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn’s and Colitis. He is an Associate Editor of the journal Gastroenterology and Editor-in-Chief of the ACG On-Line Education Universe. Dr. Rubin is an editor of Curbside Consultation in IBD (3rd ed), associate editor of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease (11th ed), and an author on >450 articles on management of IBD, including the 2019 ACG Guidelines for ulcerative colitis. He is has a verified twitter feed @IBDMD with over 20,000 followers.

David T. Rubin

Bruce Sands is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY.

Dr. Sands was awarded his BA and MD from Boston University, and trained in internal medicine at the Hospital of the University of Pennsylvania. After completing GI fellowship at the Massachusetts General Hospital, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Dr. Sands is widely recognized for his clinical investigations of new therapeutics for the inflammatory bowel diseases and has published over 250 original manuscripts. He was the lead investigator of the landmark studies ACCENT 2, UNIFI and VARSITY, published in the New England Journal of Medicine.

Bruce E. Sands

Christian brings more than 20 years of experience in clinical trial management across all development phases and many therapeutic areas in both biotech and pharma.

Christian most recently was Strategic Trial Planning Manager at Novo Nordisk delivering data-driven patient forecast. Prior to that he was Clinical Project Leader at Ferring Pharmaceuticals providing successful management of clinical trials and development programs.

Christian Friis

Séverine Vermeire is Professor of Medicine at the KU Leuven and staff member at the Gastroenterology Department of the University Hospitals Leuven.

Séverine Vermeire obtained her MD degree at the KU Leuven in 1995 and a PhD at the same University in 2001 on “Genetic Polymorphisms and Serologic Markers in Inflammatory Bowel Disease”. She further trained at the Universidad Nacional de Asuncion, Paraguay (1993), at the Welcome Trust Centre for Human Genetics , University of Oxford (1997-1998) UK and at the Montreal General Hospital (McGill University) in Canada (2000–2001). Since 2003 Dr. Vermeire is staff member at the Gastroenterology Department of the University Hospitals Leuven and is appointed Full Professor of Medicine at the KU Leuven. Since 2016, she is Head of the Department of Chronic Diseases, Metabolism & Ageing (CHROMETA) at the KU Leuven. Dr. Vermeire is actively involved as principle investigator in RCTs with new therapeutic compounds and has been lead investigator on several of these programs. Her scientific work resulted in more than 500 peer-reviewed articles so far and focusses on the role of the microbiome and genetic susceptibility in IBD and on identifying predictive signatures of treatment response. She participated in the International iCHOM consortium on development of Patient-Centered Outcomes for Inflammatory Bowel Disease. Dr. Vermeire was awarded several grants including an Advanced H2020-European Research Council (ERC) Grant (2016-2021) and a VIB Grand Challenges project on microbiota modulation strategies in Inflammatory Bowel Diseases together with Professor Jeroen Raes (2018). She was President of the European Crohn’s and Colitis Organisation (ECCO) from 2014-2016 and of the Belgian IBD Research & Development (BIRD) Group from 2011-2013.

Séverine Vermeire

Amanda Chaperot is a Partner at [Seventure Partners](/org/seventure-partners).

Amanda Chaperot

Dani Bach

Karen Wagner is a Managing Partner at [Ysios Capital](/org/ysios-capital).

Karen Wagner

Christian Elling is a Chairperson and Managing Partner at Lundbeckfonden BioCapital.

Board of Directors

About

Team members

Other teams at CytoKi Pharma

Leadership Team

CEO and Executive Team

Discover similar companies